X
Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow
https://pharmaphorum.com/news/cosmos-diarrhoea-drug-approved-threatening-salix-cash-cow/
gastroenterology
Takeda to buy stem cell specialists TiGenix for $626m
Decision follows EU regulators’ decision to back Crohn’s stem cell therapy
First ever ‘off the shelf’ stem cell therapy nears European approval
Alofisel recommended for complex perianal fistulas in Crohn’s disease
Acacia ready to file its anti-vomiting treatment
Potential launch in 2018 if FDA approves Baremsis.
Valeant could sell gastro drug unit to Takeda
Valeant may sell Salix and other units to pay off debts.
Allergan snaps up Motus for $200 million
Big pharma exercises option following gastro success.
